{"id":"direct-acting-antiviral-agents","safety":{"commonSideEffects":[{"rate":"10%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"30%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Direct-acting antiviral agents work by directly inhibiting viral enzymes or proteins, thereby blocking viral replication. This class of drugs includes protease inhibitors, polymerase inhibitors, and integrase inhibitors, among others.","oneSentence":"Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:11.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatitis C"},{"name":"Hepatitis B"}]},"trialDetails":[{"nctId":"NCT03520660","phase":"PHASE4","title":"People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2018-10-19","conditions":"Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases","enrollment":121},{"nctId":"NCT07169318","phase":"PHASE1","title":"First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-16","conditions":"Influenza","enrollment":78},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT05637879","phase":"PHASE2, PHASE3","title":"Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder","status":"RECRUITING","sponsor":"White River Junction Veterans Affairs Medical Center","startDate":"2023-12-18","conditions":"PTSD","enrollment":92},{"nctId":"NCT06928259","phase":"","title":"Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV","status":"RECRUITING","sponsor":"University of Seville","startDate":"2025-04-30","conditions":"HCV Infection","enrollment":728},{"nctId":"NCT03902366","phase":"","title":"HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-05-16","conditions":"Hepatitis C, Alcohol Use Disorder","enrollment":63},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02578693","phase":"","title":"Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":1210},{"nctId":"NCT04885855","phase":"PHASE2, PHASE3","title":"8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Muhammad Radzi Abu Hassan","startDate":"2021-03-23","conditions":"Hepatitis C","enrollment":322},{"nctId":"NCT06872047","phase":"","title":"Exploring the Knowledge, Attitudes, Behaviors and Perceived Barriers of Hepatologists Towards Non-invasive Hepatocellular Carcinoma Prediction Models in Hepatitis C Patients Who Achieved Sustained Virological Response Following Direct Acting Antivirals Therapy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-04-01","conditions":"Non-invasive Hepatocellular Carcinoma","enrollment":400},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT02824315","phase":"PHASE1","title":"Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05","conditions":"Healthy","enrollment":22},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT05368974","phase":"","title":"The Treatment in Pregnancy for Hepatitis C (\"TiP-HepC\") Registry","status":"RECRUITING","sponsor":"The Task Force for Global Health","startDate":"2022-02-11","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT04515797","phase":"PHASE4","title":"QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2021-05-01","conditions":"Kidney Failure, Hepatitis C, Kidney Disease, Chronic","enrollment":2},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT02824640","phase":"NA","title":"Patient-Centered Models of HCV Care for People Who Inject Drugs","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2016-09-15","conditions":"Hepatitis C, Medication Adherence","enrollment":755},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT06325826","phase":"","title":"The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Egyptian Liver Hospital","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":500},{"nctId":"NCT05506475","phase":"","title":"Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Institut Pasteur","startDate":"2024-05","conditions":"HIV Infection, Hepatitis C Infection","enrollment":400},{"nctId":"NCT03685045","phase":"NA","title":"ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2018-05-28","conditions":"Hepatitis C","enrollment":6000},{"nctId":"NCT04513899","phase":"NA","title":"Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2020-10-05","conditions":"Hepatitis C Virus (HCV) Infection","enrollment":10},{"nctId":"NCT04330508","phase":"","title":"Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-03-01","conditions":"Depression in Chronic Hepatitis C","enrollment":385},{"nctId":"NCT03566966","phase":"","title":"Autoantibodies and Direct-acting Antivirals","status":"COMPLETED","sponsor":"University of Bari","startDate":"2015-07-01","conditions":"Viral Hepatitis C, Therapy Adverse Effect","enrollment":191},{"nctId":"NCT05466331","phase":"NA","title":"Rural New England Health Study (Phase 2)","status":"UNKNOWN","sponsor":"Baystate Medical Center","startDate":"2022-05-18","conditions":"Hepatitis C, Opioid Use Disorder, IV Drug Usage","enrollment":220},{"nctId":"NCT03248622","phase":"","title":"Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-06-03","conditions":"Hepatitis B","enrollment":79},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT03801707","phase":"PHASE2, PHASE3","title":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-03-22","conditions":"Kidney Transplant, Hepatitis C, HCV","enrollment":54},{"nctId":"NCT04159545","phase":"","title":"Future Destinations: Journeys Towards Citizenship","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-12-15","conditions":"Hepatitis C, Drug Use","enrollment":15},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT02510300","phase":"","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-10-21","conditions":"Hepatitis C Virus Infection","enrollment":461},{"nctId":"NCT03086044","phase":"PHASE4","title":"Transplanting Hepatitis C Positive Organs","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2017-03-01","conditions":"Hepatitis C, Awaiting Organ Transplant","enrollment":148},{"nctId":"NCT04320290","phase":"PHASE4","title":"HCV + to HCV - Kidney Transplant","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-21","conditions":"Kidney Failure, Hepatitis C","enrollment":""},{"nctId":"NCT03208127","phase":"PHASE4","title":"DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-21","conditions":"End Stage Liver Disease, Hepatitis C","enrollment":33},{"nctId":"NCT04008927","phase":"NA","title":"A Community-based Intervention Among Active Drug Users in Montpellier","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-18","conditions":"Drug Use, HCV Infection","enrollment":554},{"nctId":"NCT05452187","phase":"","title":"Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study","status":"COMPLETED","sponsor":"Hospital Mutua de Terrassa","startDate":"2021-03-12","conditions":"Inflammatory Bowel Diseases, Hepatitis C Virus Infection","enrollment":79},{"nctId":"NCT03208244","phase":"PHASE4","title":"DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-09","conditions":"End Stage Heart Disease, Hepatitis C","enrollment":40},{"nctId":"NCT05376943","phase":"","title":"Possible Differences in HCC Course Depending on DAA Treatment","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2022-05-10","conditions":"Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of, Drug Effect","enrollment":100},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT04719338","phase":"NA","title":"Occult HCV Infection After DAAD Treatment in Haemodialysis Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-03-01","conditions":"Hepatitis C","enrollment":30},{"nctId":"NCT03343925","phase":"","title":"Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2018-08-17","conditions":"Hepatitis C, Chronic","enrollment":140},{"nctId":"NCT03740906","phase":"","title":"Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-09-06","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT05284916","phase":"","title":"Difference in Patterns of Liver Diseases Related Admissions After the Era of DAAS","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-03-15","conditions":"Patternsof Liver Diseasesadmissions After Era of DAAS","enrollment":200},{"nctId":"NCT02938013","phase":"PHASE4","title":"deLIVER: Direct Acting Antiviral Effects on the Liver","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"HCV Coinfection, Liver Disease, HIV","enrollment":15},{"nctId":"NCT02581020","phase":"","title":"The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-14","conditions":"Hepatitis C Virus","enrollment":344},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT03127358","phase":"NA","title":"Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2017-11-14","conditions":"Hepatitis C, Medication Adherence","enrollment":11},{"nctId":"NCT02102451","phase":"","title":"Control and Elimination Within Australia of Hepatitis C From People Living With HIV","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2014-07","conditions":"Hepatitis C, HIV, HIV-HCV Coinfection","enrollment":492},{"nctId":"NCT04251572","phase":"NA","title":"HCV Reinfection After DAA Therapy in PWID in Belgium","status":"UNKNOWN","sponsor":"Hasselt University","startDate":"2019-07-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of, Drug Use","enrollment":100},{"nctId":"NCT02247401","phase":"PHASE3","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-04","conditions":"HCV, Hepatitis C Infection, Genotype 4","enrollment":160},{"nctId":"NCT03200171","phase":"","title":"Effect of DAAs on Behavior of HCC in HCV Patients","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2018-02-10","conditions":"Carcinoma, Hepatocellular, Hepatitis C","enrollment":300},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03707080","phase":"","title":"Direct Acting Antiviral-Post Authorization Safety Study","status":"COMPLETED","sponsor":"Target PharmaSolutions, Inc.","startDate":"2018-03-09","conditions":"Hepatitis C, Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT02969668","phase":"","title":"Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Opioid-Related Disorders","enrollment":326},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT02533934","phase":"PHASE4","title":"Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"HIV, Hepatitis C, Cirrhosis","enrollment":68},{"nctId":"NCT04662138","phase":"","title":"Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-08-24","conditions":"Hepatitis C, Relapse, Antivirals","enrollment":100},{"nctId":"NCT04201808","phase":"PHASE4","title":"Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides","status":"UNKNOWN","sponsor":"New Discovery LLC","startDate":"2021-05-01","conditions":"Hepatitis B, Chronic","enrollment":100},{"nctId":"NCT02526641","phase":"","title":"Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-08","conditions":"Hepatitis C","enrollment":16},{"nctId":"NCT03820258","phase":"PHASE2","title":"Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-01-28","conditions":"Hepatitis C Virus Infection","enrollment":21},{"nctId":"NCT03444272","phase":"PHASE3","title":"Effect of Direct-acting Antiviral Drugs on Erectile Function","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-01-01","conditions":"Hepatitis C","enrollment":105},{"nctId":"NCT02441283","phase":"PHASE2, PHASE3","title":"A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06-22","conditions":"Hepatitis C","enrollment":384},{"nctId":"NCT02185794","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-06-13","conditions":"Hepatitis C Virus Infection","enrollment":101},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT02118012","phase":"PHASE1, PHASE2","title":"Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-03-20","conditions":"Chronic Hepatitis C","enrollment":24},{"nctId":"NCT03381859","phase":"PHASE4","title":"Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-12-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of","enrollment":""},{"nctId":"NCT01945008","phase":"","title":"Observational Study in HCV Chronic Infection","status":"COMPLETED","sponsor":"Istituto Superiore di Sanità","startDate":"2014-04","conditions":"Hepatitis C, Chronic","enrollment":7600},{"nctId":"NCT03602703","phase":"","title":"Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"Drug-Induced Liver Injury","enrollment":42},{"nctId":"NCT03420300","phase":"PHASE4","title":"EBR/GZR for HCV-1b Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-06-05","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02378935","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-17","conditions":"Hepatitis C Virus Infection","enrollment":205},{"nctId":"NCT02868242","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-28","conditions":"Hepatitis C Virus Infection","enrollment":19},{"nctId":"NCT04267458","phase":"PHASE4","title":"Prevalence of Kidney Injury in Patients With HCV Treated With Sofuspovir Containing DAA Therapy","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-07-01","conditions":"Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment","enrollment":300},{"nctId":"NCT03897608","phase":"","title":"Quality of Life in Patients With HCV Related Liver Cirrhosis Before and After Direct Acting Antiviral Drugs","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-02-01","conditions":"HCV Related Liver Cirrhosis Direct Acting Antiviral Drugs","enrollment":50},{"nctId":"NCT04244383","phase":"PHASE4","title":"Expression of Inflammasomes in HCV Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-01","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT04242433","phase":"","title":"HCV RAS Testing in Public Health Programs","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2017-07-16","conditions":"Hepatitis C, Public Health, Direct Acting Antiviral Agents","enrollment":200},{"nctId":"NCT04220151","phase":"","title":"Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-03-01","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT03549312","phase":"PHASE4","title":"Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy","status":"UNKNOWN","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2018-02-01","conditions":"HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence","enrollment":25},{"nctId":"NCT02064049","phase":"PHASE4","title":"Surveillance and Treatment of Prisoners With Hepatitis C","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2014-10","conditions":"Hepatitis C","enrollment":3692},{"nctId":"NCT04169464","phase":"PHASE4","title":"The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy","status":"UNKNOWN","sponsor":"MTI University","startDate":"2019-04-01","conditions":"Egyptian Patients, HCV Treatment, Kidney Function","enrollment":200},{"nctId":"NCT04159246","phase":"","title":"Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C","status":"UNKNOWN","sponsor":"Mohamed Saad","startDate":"2019-02-10","conditions":"HCV Infection","enrollment":30},{"nctId":"NCT04094272","phase":"","title":"Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Kantonsspital Olten","startDate":"2017-07-01","conditions":"Pulmonary Artery Hypertension, Chronic Hepatitis c","enrollment":49},{"nctId":"NCT03163849","phase":"PHASE3","title":"Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-09-01","conditions":"Chronic Hepatitis c","enrollment":50},{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT02993250","phase":"PHASE2","title":"A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2016-12-21","conditions":"Hepatitis C, Chronic","enrollment":33},{"nctId":"NCT04071353","phase":"","title":"Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-08-01","conditions":"Chronic Hepatitis C","enrollment":1000},{"nctId":"NCT04063839","phase":"","title":"HCV Treatment in a Low-threshold Clinic","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2015-01","conditions":"Hepatitis C, Substance Use Disorders","enrollment":300},{"nctId":"NCT02734173","phase":"PHASE4","title":"Pilot HCV Direct Acting Antiviral Therapy and Metabolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-07","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT03579576","phase":"","title":"Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar","status":"COMPLETED","sponsor":"Right to Care","startDate":"2017-12-20","conditions":"Hepatitis C, Hepatitis B, HIV Infections","enrollment":803},{"nctId":"NCT02836782","phase":"","title":"HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2016-04","conditions":"HIV","enrollment":600},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":"Hepatitis Viruses","enrollment":46},{"nctId":"NCT04017338","phase":"PHASE3","title":"Transplantation Using Hepatitis C Positive Donors, A Safety Trial","status":"UNKNOWN","sponsor":"Jordan Feld","startDate":"2018-08-06","conditions":"Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection","enrollment":40},{"nctId":"NCT03894696","phase":"","title":"Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-08-01","conditions":"Chronic Hepatitis c","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1591,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["daclatasvir","asunaprevir","ombitasvir","paritaprevir","dasabuvir"],"phase":"phase_2","status":"active","brandName":"Direct-acting antiviral agents","genericName":"Direct-acting antiviral agents","companyName":"Qing XIe","companyId":"qing-xie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins. Used for Hepatitis C, Hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}